Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cetuximab

Study to compare RT alone with cetuximab–RT for locally advanced SCCHN
Back

A

Indication details

Combined Agent(s)
Radiotherapy
Control Arm
Radiotherapy
Therapeutic Indication
Patients with SCCHN for locally advanced disease
Tumour Type
Head and neck cancer
Tumour Sub-type
Squamous cell
Tumour Stage
Locally advanced
Trial Name
Study to compare RT alone with cetuximab–RT for locally advanced SCCHN
NCT Number
NCT00004227
Trial Phase
Phase III

Approval details

FDA Approval
FDA approved
EMA Approval
EMA approved

Primary Outcome(s)

Primary Outcome(s)
Locoregional control
Evaluated Outcome
OS
Form(s)
Form 1

Outcome Data

OS Control
29.3 months, 5 year survival 36.4%
OS Gain
19.7 months, 5 year survival gain 9.2%
OS HR
0.73 (0.56-0.95)

Adjustments

QoL Comment
No QoL benefit

Score (after adjustments)

Curative score

A

Scorecard details

ESMO-MCBS version
ESMO-MCBS v1.1
Scorecard ID
384
Scorecard version
1
Issue date
07.08.2023
Cetuximab Study to compare RT alone with cetuximab–RT for locally advanced SCCHN

PRELIMINARY SCORE

OS

ADJUSTMENTS

No QoL benefit
Cetuximab Study to compare RT alone with cetuximab–RT for locally advanced SCCHN

SCORE

A

Overall Survival / Disease-Free Survival / Pathological Complete Response
Overall Survival
Progression-Free Survival
Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate
Overall Response Rate / Duration of Response
Head and neck cancer
Patients with SCCHN for locally advanced disease
Cetuximab + Radiotherapy
Radiotherapy

My watchlist

    pdf
    pptx

    Legend

    Information about symbols, abbrevations and color codes

    Red = negative
    Green = positive
    Grey = neutral
    ? Grey + ? = neutral with pending data
    DFS
    Disease-Free Survival
    DoR
    Duration of Response
    EFS
    Event-Free Survival
    HR
    Hazard Ratio
    NEB
    No evaluable benefit
    NI
    Non-inferiority Study
    ORR
    Overall Response Rate
    OS
    Overall Surival
    pCR
    Pathological Complete Response/Remission
    PFS
    Progression-Free Survival
    QoL
    Quality of Life
    RFS
    Relapse-Free Survival
    RR
    Response Rate

    QoL adjustments

    Other adjustments*

    Serious and disabling adverse effects

    Red = negative / deterioration

    Green = positive / improvement

    QoL adjustments

    Red = negative / deterioration

    Green = positive / improvement

    Other adjustments*

    Red = negative / deterioration

    Green = positive / improvement

    Serious and disabling adverse effects

    Red = negative / deterioration

    Green = positive / improvement

    * Other adjustments include:

    - Long-term plateau in the survival curve
    - Long-term plateau in the PFS curve
    - Early stopping or crossover
    - Only improved PFS mature data shows no OS advantage and no improved Qol.

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings
    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.